Prognostic Value of Mitral Regurgitation in Patients with Primary Hypertrophic Cardiomyopathy
Author:
Tesic Milorad12ORCID, Travica Lazar1, Giga Vojislav12, Jovanovic Ivana1, Trifunovic Zamaklar Danijela12ORCID, Popovic Dejana13, Mladenovic Djordje1, Radomirovic Marija1ORCID, Vratonjic Jelena1, Boskovic Nikola1, Dedic Srdjan1, Nedeljkovic Arsenovic Olga24, Aleksandric Srdjan12, Juricic Stefan1, Beleslin Branko12ORCID, Djordjevic Dikic Ana12
Affiliation:
1. Clinic for Cardiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia 2. Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia 3. Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia 4. Center for Radiology and Magnetic Resonance Imaging, University Clinical Center of Serbia, 11000 Belgrade, Serbia
Abstract
Background and Objectives: Mitral valve pathology and mitral regurgitation (MR) are very common in patients with hypertrophic cardiomyopathy (HCM), and the evaluation of mitral valve anatomy and degree of MR is important in patients with HCM. The aim of our study was to examine the potential influence of moderate or moderately severe MR on the prognosis, clinical presentation, and structural characteristics of HCM patients. Materials and Methods: A prospective study examined 176 patients diagnosed with primary asymmetric HCM. According to the severity of the MR, the patients were divided into two groups: Group 1 (n = 116) with no/trace or mild MR and Group 2 (n = 60) with moderate or moderately severe MR. All patients had clinical and echocardiographic examinations, as well as a 24 h Holter ECG. Results: Group 2 had significantly more often the presence of the obstructive type of HCM (p < 0.001), syncope (p = 0.030), NYHA II class (p < 0.001), and atrial fibrillation (p = 0.023). Also, Group 2 had an enlarged left atrial dimension (p < 0.001), left atrial volume index (p < 0.001), and indirectly measured systolic pressure in the right ventricle (p < 0.001). Patients with a higher grade of MR had a significantly higher E/e′ (p < 0.001) and, as a result, higher values of Nt pro BNP values (p < 0.001) compared to Group 1. Kaplan–Meier analysis demonstrated that the event-free survival rate during a median follow-up of 88 (IQR 40–112) months was significantly higher in Group 1 compared to Group 2 (84% vs. 45% at 8 years; log-rank 20.4, p < 0.001). After adjustment for relevant confounders, the presence of moderate or moderately severe MR remained as an independent predictor of adverse outcomes (HR 2.788; 95% CI 1.221–6.364, p = 0.015). Conclusions: The presence of moderate or moderately severe MR was associated with unfavorable long-term outcomes in HCM patients.
Reference39 articles.
1. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J. Am. Coll. Cardiol.,2020 2. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur. Heart J.,2014 3. Velicki, L., Jakovljevic, D.G., Preveden, A., Golubovic, M., Bjelobrk, M., Ilic, A., Stojsic, S., Barlocco, F., Tafelmeier, M., and Okwose, N. (2020). Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. BMC Cardiovasc. Disord., 20. 4. Popa-Fotea, N.M., Micheu, M.M., Bataila, V., Scafa-Udriste, A., Dorobantu, L., Scarlatescu, A.I., Zamfir, D., Stoian, M., Onciul, S., and Dorobantu, M. (2019). Exploring the Continuum of Hypertrophic Cardiomyopathy—From DNA to Clinical Expression. Medicina, 55. 5. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study;Maron;Am. J. Cardiol.,1994
|
|